Quanterix (QTRX) Leerink Global Healthcare Conference 2026 summary

Leadership and strategic direction

• New CEO emphasizes early stage of transformation, focusing on sustainable growth and leveraging recent Akoya acquisition for diversification beyond neurology into oncology and immunology.

• Diagnostics is a key growth driver, with a differentiated blood-based biomarker test and a 510(k) submission to the FDA; feedback expected in 6–9 months.

• A comprehensive diagnostics plan will be unveiled in the second half of the year, targeting readiness for 2027.

• Prioritization and focus are highlighted as essential for execution and sustainable growth, with an emphasis on not spreading resources too thin.

• Leadership is actively engaging with key opinion leaders and leveraging industry experience to refine strategy.

Financial performance and outlook

• Achieved synergy targets from the Akoya acquisition and maintains a strong balance sheet with $100 million in cash and no debt.

• Fourth quarter outperformed expectations, driven by recurring consumables revenue and academic funding recovery.

• 75% of revenue is now recurring, positioning the company well for 2026.

• Guidance for 2026 assumes 0–3% growth, reflecting a conservative approach amid uncertain market recovery.

• Cost structure has been right-sized, with gross margins returning to 50% and OpEx targeted at $85 million.

Diagnostics and competitive positioning

• The diagnostics test offers a 10% indeterminate zone, providing 90% of patients with actionable results and risk scores for ongoing monitoring.

• Differentiation is based on sensitivity, specificity, and ease of use, with competitors facing higher indeterminate rates and workflow challenges.

• $897 Medicare reimbursement pricing has been secured, with broader payer engagement ongoing and clinical utility data expected to support further coverage.

• Competition is viewed as a motivator for innovation and market validation.